AP2002002586A0 - Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. - Google Patents

Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.

Info

Publication number: AP2002002586A0
Authority: AP; ARIPO
Prior art keywords: substituted lower; compounds; nr9r10; pyrido; pyrimidine
Prior art date: 2000-01-25

Application number

APAP/P/2002/002586A

Other languages

English (en)

Inventor

Richard John Booth

Ellen Myra Dobrusin

Vara Prasad Venkata Negendra Josyula

Dennis Joseph Mcnamara

Peter Laurence Toogood

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-25

Filing date

2001-01-23

Publication date

2002-09-30

2001-01-23 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2002-09-30 Publication of AP2002002586A0 publication Critical patent/AP2002002586A0/en

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
QRRCMVPZJCHBLQ-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-2,7-diamine Chemical compound C1=NC(N)=NC2=NC(N)=CC=C21 QRRCMVPZJCHBLQ-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
101150020251 NR13 gene Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

APAP/P/2002/002586A 2000-01-25 2001-01-23 Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. AP2002002586A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17826100P	2000-01-25	2000-01-25
PCT/IB2001/000069 WO2001055147A1 (fr)	2000-01-25	2001-01-23	Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase

Publications (1)

Publication Number	Publication Date
AP2002002586A0 true AP2002002586A0 (en)	2002-09-30

Family

ID=22651853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2002/002586A AP2002002586A0 (en)	2000-01-25	2001-01-23	Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.

Country Status (34)

Country	Link
EP (1)	EP1254137A1 (fr)
JP (1)	JP4047010B2 (fr)
KR (1)	KR20020065939A (fr)
CN (1)	CN1395578A (fr)
AP (1)	AP2002002586A0 (fr)
AR (1)	AR030044A1 (fr)
AU (1)	AU2542501A (fr)
BG (1)	BG106850A (fr)
BR (1)	BR0107751A (fr)
CA (1)	CA2397961C (fr)
CO (1)	CO5261549A1 (fr)
CR (1)	CR6706A (fr)
CZ (1)	CZ20022475A3 (fr)
DZ (1)	DZ3266A1 (fr)
EA (1)	EA200200643A1 (fr)
EE (1)	EE200200405A (fr)
GT (1)	GT200100016A (fr)
HN (1)	HN2001000013A (fr)
HU (1)	HUP0204141A3 (fr)
IL (1)	IL150545A0 (fr)
IS (1)	IS6443A (fr)
MA (1)	MA26868A1 (fr)
MX (1)	MXPA02007221A (fr)
NO (1)	NO20023527L (fr)
OA (1)	OA12161A (fr)
PA (1)	PA8510701A1 (fr)
PE (1)	PE20011066A1 (fr)
PL (1)	PL356802A1 (fr)
SK (1)	SK10632002A3 (fr)
SV (1)	SV2002000294A (fr)
TN (1)	TNSN01014A1 (fr)
WO (1)	WO2001055147A1 (fr)
YU (1)	YU50402A (fr)
ZA (1)	ZA200205879B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de)	2000-10-23	2011-09-15	Glaxosmithkline Llc	Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
PE20030008A1 (es) *	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
BR0316680A (pt) *	2002-11-28	2005-10-18	Schering Ag	Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
TW200502236A (en)	2003-03-28	2005-01-16	Hoffmann La Roche	Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr)	2004-07-15	2007-11-23	Sanofi Synthelabo	Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) *	2004-09-21	2007-08-08	霍夫曼-拉罗奇有限公司	用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类
UY29439A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
UY29440A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
EP1865959A2 (fr)	2005-03-25	2007-12-19	Glaxo Group Limited	Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
WO2006110298A2 (fr)	2005-03-25	2006-10-19	Glaxo Group Limited	Nouveaux composes
FR2887882B1 (fr)	2005-07-01	2007-09-07	Sanofi Aventis Sa	Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (fr) *	2005-07-21	2007-01-25	F. Hoffmann-La Roche Ag	Composes pyrido [2, 3-d] pyrimidine-2, 4-diamine utilises comme inhibiteurs de ptp1b
ATE482958T1 (de) *	2005-08-09	2010-10-15	Irm Llc	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
FR2896246B1 (fr)	2006-01-13	2008-08-15	Sanofi Aventis Sa	Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (fr)	2006-10-16	2008-04-23	GPC Biotech Inc.	Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
FR2910813B1 (fr)	2006-12-28	2009-02-06	Sanofi Aventis Sa	Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (fr)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Inhibiteurs Raf améliorés
WO2010063352A1 (fr) *	2008-12-01	2010-06-10	Merck Patent Gmbh	Pyrido[4,3-d]pyrimidines 2,5-diamino-substituées en tant qu'inhibiteurs d'autotaxine contre le cancer
GB201104267D0 (en)	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
GB201216018D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Pharmacologically active compounds
WO2014151682A1 (fr)	2013-03-14	2014-09-25	Icahn School Of Medicine At Mount Sinai	Composés pyrimidines en tant qu'inhibiteurs de kinase
GB201403536D0 (en)	2014-02-28	2014-04-16	Cancer Rec Tech Ltd	Inhibitor compounds
KR101671404B1 (ko) *	2014-09-02	2016-11-02	한국원자력의학원	항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) *	2016-04-11	2019-07-02	上海勋和医药科技有限公司	杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en)	2017-06-20	2017-08-02	Inst Of Cancer Research: Royal Cancer Hospital	Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
HUT76853A (en) *	1994-11-14	1997-12-29	Warner Lambert Co	6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU763839B2 (en) *	1998-05-26	2003-07-31	Warner-Lambert Company	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

2001
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 CA CA002397961A patent/CA2397961C/fr not_active Expired - Fee Related
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/fr not_active Ceased
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 EP EP01900591A patent/EP1254137A1/fr not_active Withdrawn
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Ceased
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2397961C (fr)	2008-08-26
CZ20022475A3 (cs)	2003-03-12
JP4047010B2 (ja)	2008-02-13
NO20023527D0 (no)	2002-07-24
IS6443A (is)	2002-06-25
BG106850A (bg)	2003-02-28
CO5261549A1 (es)	2003-03-31
MXPA02007221A (es)	2002-11-29
SV2002000294A (es)	2002-07-16
ZA200205879B (en)	2003-09-29
MA26868A1 (fr)	2004-12-20
CR6706A (es)	2005-04-04
NO20023527L (no)	2002-09-10
TNSN01014A1 (fr)	2005-11-10
BR0107751A (pt)	2002-11-12
PA8510701A1 (es)	2002-12-11
HUP0204141A3 (en)	2005-03-29
OA12161A (en)	2006-05-08
HN2001000013A (es)	2001-06-18
EA200200643A1 (ru)	2002-12-26
PE20011066A1 (es)	2001-10-22
AU2542501A (en)	2001-08-07
SK10632002A3 (sk)	2003-06-03
CA2397961A1 (fr)	2001-08-02
HUP0204141A2 (hu)	2003-04-28
KR20020065939A (ko)	2002-08-14
EE200200405A (et)	2003-12-15
AR030044A1 (es)	2003-08-13
IL150545A0 (en)	2003-02-12
CN1395578A (zh)	2003-02-05
EP1254137A1 (fr)	2002-11-06
PL356802A1 (en)	2004-07-12
JP2003523357A (ja)	2003-08-05
WO2001055147A1 (fr)	2001-08-02
DZ3266A1 (fr)	2001-08-02
YU50402A (sh)	2005-11-28
GT200100016A (es)	2001-10-19

Publication	Publication Date	Title
AP2002002586A0 (en)	2002-09-30	Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
BG106594A (en)	2002-12-29	Pteridinones as kinase inhibitors
RU2441869C2 (ru)	2012-02-10	Противовирусные соединения
AP2000001964A0 (en)	2000-12-31	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MXPA02011974A (es)	2004-09-06	Derivados de quinazolina sustituidos y su uso como inhibidores.
NZ627709A (en)	2014-12-24	Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
RU2005127052A (ru)	2006-02-10	Соединения тиенопиримидина и их применение
GEP20063915B (en)	2006-09-11	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
MY141739A (en)	2010-06-15	Substituted quinazoline derivatives as inhibitors of aurora kinases
HRP20120351T1 (hr)	2012-05-31	Macrociklički derivati kinazolina kao antiproliferativna sredstva
GEP20156282B (en)	2015-05-11	Compounds and compositions as protein kinase inhibitors
EP0591528A4 (fr)	1995-02-15	DERIVE DE PYRAZOLO 1,5-a]PYRIMIDINE ET AGENT ANTI-INFLAMMATOIRECONTENANT CE DERIVE.
IL150883A0 (en)	2003-02-12	Pyrimidine compounds
BRPI0517461A (pt)	2008-10-07	compostos farmacêuticos
AR006906A1 (es)	1999-09-29	Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
TR199900481T2 (xx)	1999-06-21	�ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
MY141220A (en)	2010-03-31	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1233950A4 (fr)	2003-03-26	Composes de 3,4-dihydro-(1h)quinazolin-2-one comme inhibiteurs de csbp/p38 kinase
CA2997039A1 (fr)	2017-03-09	Compose pyrimidine a substitution 2,4-di-(groupe azote), son procede de preparation et son utilisation
CN117751104A (zh)	2024-03-22	一类具有激酶抑制功能的化合物及其制备和应用
DK0888356T3 (da)	2002-06-03	Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
TH53887A (th)	2002-11-18	ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส
DE60214554D1 (de)	2006-10-19	Derivate von 3-phenyl-n-(2-(4-benzyl)piperidin-1-yl)ethyl) acrylamid mit ccr-3-rezeptor antagonistischer wirkung zur verwendung bei der behandlung von entzündungen und allergischen leiden
PE20020513A1 (es)	2002-08-24	COMPUESTOS DE 2,4,8-TRISUSTITUIDA-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA